The markets opened higher with the Dow climbing 91 points to 20,544 after last week's sharp losses as investors snapped up bargains. Nasdaq gained 28 points to 5,833.
On the upside
Abbott (NYSE: ABT) amended its agreement to acquire Alere (NYSE: ALR) for a reduced price of $5.3 billion.
The European Medicines Agency accepted Cleveland BioLabs' (Nasdaq: CBLI) pediatric investigation plan.
HTG Molecular Diagnostics (Nasdaq: HTGM) entered into a research agreement with Centre Leon Berard for molecular profiling studies and entered into a master services agreement with Daiichi Sankyo for work to be performed in HTG's VERI/O laboratory.
On the downside
Snyder's-Lance (Nasdaq: LNCE) announced the retirement of president and chief executive Carl E. Lee and forecast disappointing results.
The Food and Drug Administration issued a Complete Response Letter to Eli Lilly & Co. (NYSE: LLY) and Incyte (Nasdaq: INCY) for their moderate-to-severe rheumatoid arthritis treatment.
Vince Holding (NYSE: VNCE) will delay the release of its fourth quarter and full year financials.
In the broad market, advancing issues outpaced decliners by a margin of nearly 3 to 1 on the NYSE and by more than 2 to 1 on Nasdaq. The broader S&P 500 index climbed 10 points to 2,339. Bitcoin lost $2 to $1176.
